Revtorpyk (Gedatolisib)

Gedatolisib is a medicine used to treat a type of advanced breast cancer that has kept growing after hormone therapy. It works by blocking a signal pathway that cancer cells use to grow. It's given as an infusion into a vein, together with other breast cancer medicines.

Brand names:Revtorpyk
Medication

What people taking Revtorpyk (Gedatolisib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Revtorpyk (Gedatolisib) for Breast Cancer?

NameHow it went

About Revtorpyk (Gedatolisib)

What It's For

Gedatolisib, sold as Revtorpyk, is a targeted cancer medicine for adults with a specific kind of advanced breast cancer. The cancer must be hormone receptor-positive, meaning estrogen or progesterone fuels its growth, and HER2-negative, meaning it does not make too much of a growth protein called HER2. It is used when the cancer has spread or cannot be removed with surgery, and has kept growing despite at least one hormone-blocking treatment given for advanced disease. It is approved only for cancers in which testing finds no mutation in a gene called PIK3CA. That mutation is common in this type of breast cancer and points toward different targeted drugs, so the result of tumor testing helps decide whether gedatolisib is an option. Gedatolisib is always given together with fulvestrant (Faslodex), a hormone therapy injection, and sometimes also with palbociclib (Ibrance), a daily pill that slows cancer cell division. It was approved in the US in 2026. Like other treatments for advanced breast cancer, its aim is to control the cancer for as long as possible, not to cure it.

How It Works

Inside cells, a chain of signaling proteins known as the PI3K/AKT/mTOR pathway works like a growth switch, telling the cell to grow, divide and survive. Breast cancers that depend on estrogen often lean on this pathway too, especially after hormone therapy stops working. Gedatolisib blocks the pathway at two levels: PI3K near the start of the chain and mTOR further along. Because it does not rely on one mutated form of PI3K, it can act in tumors without a PIK3CA mutation. Fulvestrant, given alongside it, attaches to the estrogen receptor and lowers the amount of it in cancer cells, cutting off the hormone signal. Together they attack two growth signals the cancer uses. The same pathway helps the body manage blood sugar, which is why high blood sugar is an expected side effect of drugs in this group.

Dosage & Administration

Gedatolisib is given in a clinic or infusion center as a 30-minute infusion into a vein. The usual schedule is once a week for three weeks, then a week off, repeating every 28 days. If a dose is delayed, it is given as soon as possible rather than skipped, and later doses are shifted to keep the three-weeks-on, one-week-off pattern. In the main study, VIKTORIA-1, fulvestrant was given as a shot into the muscle twice in the first month and then monthly, and palbociclib, when used, was a pill taken daily for three weeks out of four. Treatment continues as long as the cancer stays under control and side effects remain manageable. If side effects become significant, the care team may pause gedatolisib or lower the dose. When gedatolisib starts, the care team prescribes a steroid-containing, alcohol-free mouthwash to prevent mouth sores. It is used four times a day for at least the first eight weeks, and longer if needed, with no eating or drinking for an hour after each use. It is meant to be started on day one rather than once sores appear, because sores often begin within the first week.

Side Effects

Mouth sores, called stomatitis, are the most common problem. In the main study they affected about 7 in 10 people on the three-drug combination and nearly 6 in 10 on gedatolisib with fulvestrant, and about 1 in 5 people on the three-drug combination had severe sores. Severe mouth sores and rash were more common in people 65 and older. Painful redness, swelling or sores in the mouth should be reported to the care team, who can step up the mouthwash and add other treatments. Other common effects include nausea, tiredness, vomiting, diarrhea or constipation, taste changes, itching and less appetite. Blood tests often show lower blood counts and raised liver enzymes. Low blood counts are more frequent when palbociclib is part of the regimen, and with palbociclib, fever, chills, shortness of breath or unusual bleeding or bruising should be reported to the care team right away, since they can signal infection or low blood counts. Rash affected 3 to 4 in 10 people and was sometimes severe. Limiting sun exposure during treatment is advised, and a new rash should be reported to the care team right away. Less often, people had serious problems such as pneumonia or blood clots.

Interactions & Warnings

Gedatolisib can cause severe high blood sugar. Fasting blood sugar and HbA1c (a blood test that reflects average blood sugar over about three months) are checked before treatment and regularly during it, and blood sugar should be well controlled before each infusion. People with well-controlled type 2 diabetes may need more diabetes medicine and closer monitoring, and anyone with an HbA1c of 6.5% or higher (the range used to diagnose diabetes) is asked to check blood sugar at home. Its safety has not been established in type 1 diabetes or poorly controlled type 2 diabetes. Unusual thirst, urinating more often, blurred vision, confusion, trouble breathing, or a bigger appetite with weight loss can be signs of high blood sugar and call for contacting the care team right away. Gedatolisib can harm a developing baby, so a pregnancy test is done before starting. Because it is always given with fulvestrant, the care team uses the longest protection period required by any drug in the combination. Women who could become pregnant should use effective contraception, and should not breastfeed, during treatment and for one year after the last fulvestrant dose. Men with partners who could become pregnant should use contraception for at least 2 weeks after the last gedatolisib dose, or for 3 months after the last dose when palbociclib is part of treatment. Animal studies suggest it may also reduce fertility. The gedatolisib label does not list specific medicines to avoid, but palbociclib interacts with grapefruit and with some medicines, including certain antifungals, antibiotics and seizure medicines. The care team and pharmacist should see a full list of prescriptions, over-the-counter medicines and supplements.

What to Expect

In VIKTORIA-1, everyone had already been treated with a CDK4/6 inhibitor (the drug class that includes palbociclib) and a hormone therapy called an aromatase inhibitor. Half of people on gedatolisib, fulvestrant and palbociclib went about 9 months or longer before their cancer grew, and about 7 months on gedatolisib and fulvestrant, compared with 2 months on fulvestrant alone. About 3 in 10 people with measurable tumors saw them shrink on a gedatolisib combination. Whether it helps people live longer was not yet known when it was approved. The early weeks are usually the most demanding: weekly infusions, mouthwash four times a day, and mouth sores that often start early. Blood tests track blood counts, liver function and blood sugar, and scans show whether the cancer is responding. Pauses and dose reductions are common (about 4 in 10 people on the three-drug combination had a lower dose at some point) and are part of keeping treatment going. When the cancer starts growing again or side effects become too hard to manage, the oncologist discusses what comes next.

Questions to Ask Your Doctor

  1. 1.Has my tumor been tested for a PIK3CA mutation, and how does the result shape my options?
  2. 2.Would you recommend gedatolisib with fulvestrant alone or with palbociclib as well, and why?
  3. 3.What should I do if mouth sores develop even though I am using the mouthwash?
  4. 4.Do my blood sugar or HbA1c results mean I need home glucose checks or diabetes medicine during treatment?
  5. 5.What other treatments could I consider instead, and what would come next if this one stops working?

Last reviewed • Oct 2026

Educational content, not medical advice.